JFrog Q3 Non-GAAP Earnings, Revenue Rise; Guides Q4, 2026 Guidance Raised; Shares Gain After Hours

MT newswire2026/11/05 21:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

05:01 PM EST, 11/05/2026 (MT Newswires) -- JFrog (FROG) reported Q3 non-GAAP earnings late Thursday of $0.32 per diluted share, up from $0.22 a year earlier. Analysts polled by FactSet expected $0.23. Revenue in the three months ended Sept. 30 rose to $179.2 million from $136.9 million a year earlier. Analysts projected $165.9 million. The company expects Q4 non-GAAP EPS of $0.28 to $0.30, on revenue of $183 million to $185 million. Analysts project EPS of $0.21 on revenue of $168.3 million. JFrog boosted full-year guidance to non-GAAP EPS of $1.14 to $1.16 on revenue of $680 million to $682 million. The prior forecast was EPS of $0.96 to $1.00 on revenue of $648 million to $652 million. Analysts expect EPS of $0.98 on revenue of $651.9 million. JFrog shares jumped almost 28% in after-hours trading.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.

华尔街见闻•2026/11/09 22:12